Skip to main content
Apeloa Pharmaceutical Co.,Ltd. logo

Apeloa Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 000739 ISIN · CNE000000Q45 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,841 across all filing types
Latest filing 2023-03-09 Annual Report
Country CN China
Listing Shenzhen Stock Exchange 000739

About Apeloa Pharmaceutical Co.,Ltd.

https://www.apeloa.com

Apeloa Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and distribution of active pharmaceutical ingredients (APIs), intermediates, and finished dosage forms. The company operates three core business pillars: API production, Contract Development and Manufacturing Organization (CDMO) services, and finished drug products. Its therapeutic focus includes cardiovascular, anti-infective, anti-viral, and oncology treatments. Apeloa utilizes an integrated supply chain to deliver chemical and biological solutions to a global client base. The organization maintains compliance with international quality standards, including certifications from the FDA, EMA, and PMDA. Its CDMO services encompass the full product lifecycle, from process chemistry and analytical development to large-scale commercial manufacturing, supported by specialized technology platforms such as continuous flow chemistry and enzymatic synthesis.

Recent filings

Filing Released Lang Actions
2022年年度报告摘要
Annual Report Classification · 95% confidence The document is titled as "2022 年年度报告摘要" which translates to "2022 Annual Report Summary". It contains detailed financial data for the year 2022, including main accounting data, financial indicators, quarterly data, shareholder information, and business overview. The document is about 4410 characters long, which is relatively short but contains substantive financial data and analysis, not just an announcement or a link to a report. It is a summary of the full annual report, which is typical for an Annual Report (10-K) or equivalent. There is no indication that this is merely an announcement or a certification. The content aligns with the definition of an Annual Report, covering company activity and full financial performance for the fiscal year 2022. Therefore, the appropriate classification is Annual Report (10-K). FY 2022
2023-03-09 Chinese
年度股东大会通知
AGM Information Classification · 95% confidence The document is a detailed notice about the convening of the 2022 Annual General Meeting (AGM) of 普洛药业股份有限公司, including the meeting date, voting procedures, proposal list, and proxy voting instructions. It contains no actual financial statements or results but rather the agenda and procedural information for the AGM. The document length is about 5,348 characters, which is consistent with a meeting notice rather than a full annual report or financial report. The content focuses on the announcement and logistics of the AGM, including proposals to be voted on, but does not include the results or detailed financial data. Therefore, this document fits the category of AGM Information (AGM-R).
2023-03-09 Chinese
独立董事述职报告 （潘伟光）
Board/Management Information Classification · 95% confidence The document is titled '2022 年度独立董事述职报告' which translates to '2022 Annual Independent Director's Work Report'. It details the independent director's attendance at board meetings, opinions on company matters, committee work, and efforts to protect investor rights during the year 2022. The content focuses on governance activities and the director's role rather than financial results or audit findings. It is not an annual report, audit report, or earnings release. It is a management or board-related report specifically from an independent director about their duties and opinions. This fits best under Board/Management Information (MANG) as it relates to board activities and management oversight rather than financial reporting or regulatory filings. The document length is short (1547 characters), but it is a substantive report, not just an announcement or certification, so it is not RPA or RNS. Therefore, the classification is MANG with high confidence.
2023-03-09 Chinese
2022年年度报告
Annual Report Classification · 100% confidence The document is titled "2022 年年度报告" (2022 Annual Report) of 普洛药业股份有限公司 (Apeloa Pharmaceutical Co., Ltd.). It includes detailed sections such as company overview, main financial indicators, management discussion and analysis, corporate governance, environmental and social responsibility, important matters, shareholding changes, preferred shares, bonds, and financial statements. The document contains comprehensive financial data, management analysis, and detailed disclosures typical of a full annual report. The length is substantial (15,000 characters), and it is not a mere announcement or certification. Therefore, it fits the definition of an Annual Report (10-K). FY 2022
2023-03-09 Chinese
内部控制自我评价报告
Audit Report / Information Classification · 95% confidence The document is titled '2022 年度内部控制评价报告' which translates to '2022 Annual Internal Control Evaluation Report'. It is a detailed report on the company's internal control evaluation for the year ending December 31, 2022. The content includes detailed descriptions of internal control systems, evaluation criteria, scope, and conclusions about the effectiveness of internal controls over financial and non-financial reporting. It also includes audit opinions and compliance with regulatory standards. The document is lengthy (over 12,000 characters) and contains substantive content rather than just an announcement or certification. This type of report is typically classified as an Audit Report / Information (AR) because it focuses on internal control evaluation and audit-related information rather than being a full annual report (10-K) or other categories like earnings release or management reports. Therefore, the appropriate classification is AR with high confidence. FY 2022
2023-03-09 Chinese
内部审计管理制度（2023 制定）
Governance Information Classification · 95% confidence The document is titled '内部审计管理制度' which translates to 'Internal Audit Management System'. It details the internal audit policies, responsibilities, procedures, and organizational structure of the company's internal audit function. It does not contain financial statements, financial results, or any report of financial performance. It is a governance-related document outlining internal control and audit management rules. It is not an announcement, transcript, or report of financial results or voting. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2023-03-09 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.